Table 3 Observed PNEN patients at our institute
From: Reconsideration of operative indications in pancreatic neuroendocrine neoplasms
Case | Age | Sex | Size (mm) | Morphological change | Growth rate (mm/year) | EUS-FNA | Location | NSE | Overall survival (months) | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|
1 | 53 | Female | 11 | 8 mm→11 mm | 0.31 | – | Tail | 10.1 | 114.3 | Alive |
2 | 78 | Male | 8 | 8 mm→8 mm | 0 | – | Body | 14.5 | 55.8 | Alive |
3 | 70 | Male | 9 | 8 mm→9 mm | 0.40 | G2 | Head | 9.3 | 30.3 | Alive |
4 | 51 | Male | ① 17 (tail) ②12 (body) ③14 (head) ④ 8 (head) | ①17 mm→16 mm ②12 mm→13 mm ③14 mm→16 mm ④8 mm→8.7 mm | ①-0.41 ②0.41 ③0.82 ④0.29 | G1 | Multiple | 10.8 | 29.2 | Alive |
5 | 60 | Male | 12 | 12 mm→12 mm | 0 | – | Head | 14.4 | 103.0 | Alive |
6 | 66 | Male | 9 | 9 mm→9 mm | 0 | – | Head | 9.4 | 46.5 | Alive |
7 | 35 | Male | 8 | 8 mm→10 mm | 0.84 | – | Head | N.E. | 28.5 | Alive |
8 | 86 | Female | 15 | 15 mm→17 mm | 0.83 | – | Tail | N.E. | 29.0 | Alive |
9 | 35 | Female | 8 | 8 mm→8 mm | 0 | – | Body | N.E. | 56.3 | Alive |
10 | 70 | Male | 7 | 7 mm→7 mm | 0 | – | Body | N.E. | 58.1 | Alive |
11 | 73 | Male | 5 | 5 mm→8 mm | 0.99 | – | Head | N.E. | 36.5 | Alive |
12 | 48 | Male | 7 | 7 mm→7 mm | 0 | – | Body | N.E. | 13.3 | Alive |
13 | 60 | Female | 7 | 7 mm→7 mm | 0 | – | Body | N.E. | 38.9 | Alive |
14 | 78 | Male | 7 | 7 mm→8 mm | 0.35 | – | Body | N.E. | 34.7 | Alive |
15 | 71 | Female | 13 | 13 mm→13 mm | 0 | G2 | Tail | N.E. | 16.0 | Alive |
16 | 88 | Male | 23 | 23 mm→25 mm | 3.33 | – | Body | N.E. | 7.2 | Alive |
17 | 62 | Female | 19 | 19 mm→19 mm | 0 | G1 | Head | N.E. | 2.4 | Alive |